Mana Capital Acquisition (MAAQ) Competitors $0.53 -0.04 (-6.92%) As of 01/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends MAAQ vs. PULM, FBRX, CARA, ATHA, COCP, TRAW, GOVX, APRE, CYTH, and MIRAShould you be buying Mana Capital Acquisition stock or one of its competitors? The main competitors of Mana Capital Acquisition include Pulmatrix (PULM), Forte Biosciences (FBRX), Cara Therapeutics (CARA), Athira Pharma (ATHA), Cocrystal Pharma (COCP), Traws Pharma (TRAW), GeoVax Labs (GOVX), Aprea Therapeutics (APRE), Cyclo Therapeutics (CYTH), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. Mana Capital Acquisition vs. Pulmatrix Forte Biosciences Cara Therapeutics Athira Pharma Cocrystal Pharma Traws Pharma GeoVax Labs Aprea Therapeutics Cyclo Therapeutics MIRA Pharmaceuticals Mana Capital Acquisition (NASDAQ:MAAQ) and Pulmatrix (NASDAQ:PULM) are both small-cap unclassified companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, community ranking, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership. Is MAAQ or PULM more profitable? Mana Capital Acquisition has a net margin of 0.00% compared to Pulmatrix's net margin of -96.51%. Mana Capital Acquisition's return on equity of 0.00% beat Pulmatrix's return on equity.Company Net Margins Return on Equity Return on Assets Mana Capital AcquisitionN/A N/A N/A Pulmatrix -96.51%-45.97%-30.72% Do insiders & institutionals hold more shares of MAAQ or PULM? 68.4% of Mana Capital Acquisition shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 0.6% of Pulmatrix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer MAAQ or PULM? Pulmatrix received 195 more outperform votes than Mana Capital Acquisition when rated by MarketBeat users. However, 100.00% of users gave Mana Capital Acquisition an outperform vote while only 48.28% of users gave Pulmatrix an outperform vote. CompanyUnderperformOutperformMana Capital AcquisitionOutperform Votes1100.00% Underperform VotesNo VotesPulmatrixOutperform Votes19648.28% Underperform Votes21051.72% Which has stronger valuation & earnings, MAAQ or PULM? Mana Capital Acquisition has higher earnings, but lower revenue than Pulmatrix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMana Capital AcquisitionN/AN/AN/AN/AN/APulmatrix$7.30M2.99-$14.12M-$2.64-2.27 Does the media prefer MAAQ or PULM? In the previous week, Mana Capital Acquisition's average media sentiment score of 0.00 equaled Pulmatrix'saverage media sentiment score. Company Overall Sentiment Mana Capital Acquisition Neutral Pulmatrix Neutral SummaryMana Capital Acquisition beats Pulmatrix on 5 of the 8 factors compared between the two stocks. Get Mana Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for MAAQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAAQ vs. The Competition Export to ExcelMetricMana Capital AcquisitionIn Vitro, In Vivo Diagnostic Substances IndustryUnclassified SectorNASDAQ ExchangeMarket Cap$4.30M$4.30M$123.11M$9.13BDividend YieldN/AN/A5.15%4.00%P/E RatioN/AN/A1.1717.53Price / SalesN/AN/A13.82134.37Price / CashN/AN/A91.8332.90Price / BookN/AN/A1.014.69Net IncomeN/AN/A$1.73M$224.57M7 Day Performance-21.07%-21.07%-0.80%3.33%1 Month Performance-45.62%-45.62%23.69%5.33%1 Year Performance-76.14%-76.14%28.30%22.97% Mana Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAAQMana Capital AcquisitionN/A$0.53-6.9%N/A-76.1%$4.30MN/A0.001High Trading VolumePULMPulmatrix0.411 of 5 stars$5.90-1.5%N/A+237.9%$21.55M$10.01M-2.2320Positive NewsFBRXForte Biosciences3.3739 of 5 stars$14.62-8.6%$23.58+61.3%+52,641.1%$21.37MN/A-0.905Analyst ForecastNews CoverageCARACara Therapeutics4.0244 of 5 stars$4.67+0.2%$27.84+496.1%-32.2%$21.34M$8.69M-2.6780ATHAAthira Pharma3.5797 of 5 stars$0.53+0.2%$13.83+2,500.3%-81.3%$20.57MN/A-0.1940Gap UpCOCPCocrystal Pharma2.2659 of 5 stars$1.99-4.3%$7.00+251.8%+20.7%$20.25MN/A-1.0810Positive NewsGap DownTRAWTraws Pharma0.5233 of 5 stars$6.68-8.9%N/AN/A$20.21M$226,000.00-0.0517Gap DownGOVXGeoVax Labs2.7147 of 5 stars$2.11-0.5%$14.20+573.0%-50.7%$19.91M$3.09M0.0010Positive NewsAPREAprea Therapeutics3.8135 of 5 stars$3.62+5.8%$15.50+328.2%-24.9%$19.68M$580,000.00-1.297News CoveragePositive NewsGap DownCYTHCyclo Therapeutics1.7478 of 5 stars$0.68+3.0%$0.95+39.7%-48.1%$19.56M$1.08M-0.769Gap DownMIRAMIRA Pharmaceuticals2.683 of 5 stars$1.17-1.7%$14.00+1,096.6%+40.9%$19.38MN/A-2.092Positive News Related Companies and Tools Related Companies PULM Alternatives FBRX Alternatives CARA Alternatives ATHA Alternatives COCP Alternatives TRAW Alternatives GOVX Alternatives APRE Alternatives CYTH Alternatives MIRA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MAAQ) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mana Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mana Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
